



以技术为支柱  
以效率为引擎





AI 2025 4 FDA  
NAMs NAMs

NAMs

NAMs

AI

&

&

&

NAMs

NAMs

AI  
(*in vitro*)

(*ex vivo*)

(*in silico*)



3D

Organ-on-Chip

MPS

Organoid



PBPK

QSP

QST


/



NAMs

NAMs

## NAMs



AI

Target-to-hit Hit-to-lead Lead-to-PCC



- GPCRs
- 
- 

- CellTiter Glo/LDH/MTT/CCK-8
- / /
- HepG2, HUVEC, HEK293, SH-SY5Y
- PBMC

- ROS
- 

- hERG
- Nav1.5 Cav1.2
- iPSC -2D/3D

- HepG2/ - Seahorse
- 
- ROS

- MDCK HEK293 Vero HK-2
- 

- Mini-AMES
- AMES
- AMES
- 
- 


- 12 43
- -CTG LDH
- -RNAseq
- 



- /PBMC
- T /
- B /
- (MLR)
- PBMC-PDXO

- 3T3



- 

- 
- 
- 







9





& &




ABT-263 24 CTG  
ABT-263

ADP 5 anti-CD42 anti-CD62P  
ADP

CD62P+ cells

& &




HepG2  
mRNA

siRNA 10 nM


siRNA


& &




Smarca2/4 PROTAC MV-4-11 (DMSO, 10 nM, 100 nM),  
Smarca2 Smarca4 100nM

A B PROTAC 10nM






LDH




- 0.1x10<sup>6</sup> cells/
- 0.2x10<sup>6</sup> cells/
- 0.4x10<sup>6</sup> cells/
- PBMC 4






PBMC

PDXO



Microscopy



NAMs

NAMs

FDA

